Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

With an eye towards an IND
March 2020
SHARING OPTIONS:

CAMBRIDGE, Mass.—Kintai Therapeutics, a Flagship Pioneering company, has advanced KTX-0200 into IND-enabling studies after the anti-obesity agent demonstrated efficacy in preclinical studies. KTX-0200 resulted in sustained weight loss of 14 percent in chronic diet-induced obesity rodent models, as well as a 12-percent improvement in oral glucose clearance (per an oral glucose tolerance test) and a 14.5-percent improvement in insulin sensitivity (based on glucose clearance in an insulin tolerance test). The compound also demonstrated significant improvements in liver health in animal models; in the Gubra NASH model, KTX-0200 treatment led to a 30-percent reduction in liver fat, a 19-percent decrease in total liver weight and a 38-percent decrease in liver transaminases known to be indicative of liver damage. KTX-0200 is a novel, oral, small-molecule agent, and has been shown to lead to weight loss with little change in eating habits.
 
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.